Copyright
©The Author(s) 2022.
World J Crit Care Med. May 9, 2022; 11(3): 149-159
Published online May 9, 2022. doi: 10.5492/wjccm.v11.i3.149
Published online May 9, 2022. doi: 10.5492/wjccm.v11.i3.149
Table 1 Patient baseline characteristics and presentation by unit
Overall, n = 109 | MSICU, (n = 49) | CCU, (n = 60) | P value1 | |
Age (yr), mean (SD) | 67.2 (14.2) | 64.9 (14.4) | 69 (13.7) | 0.13 |
Female gender – n (%) | 78 (71.6) | 30 (61.2) | 48 (80.0) | 0.04 |
Race/Ethnicity – n (%) | 0.37 | |||
White | 30 (27.5) | 17 (34.7) | 13 (21.7) | |
Black | 20 (18.4) | 9 (18.4) | 11 (18.3) | |
Hispanic | 42 (38.5) | 15 (30.6) | 27 (45.0) | |
Other | 17 (15.6) | 8 (16.3) | 9 (15.0) | |
Comorbidities – n (%) | ||||
Diabetes mellitus | 40 (36.7) | 19 (38.8) | 21 (35) | 0.68 |
Hypertension | 65 (59.6) | 23 (46.9) | 42 (70) | 0.01 |
Coronary disease | 13 (11.9) | 5 (10.2) | 8 (13.3) | 0.77 |
Heart failure | 7 (6.4) | 4 (8.2) | 3 (5) | 0.70 |
Arrhythmia | 14 (12.8) | 4 (8.2) | 10 (16.7) | 0.25 |
Asthma | 16 (14.7) | 6 (12.2) | 10 (16.7) | 0.52 |
COPD | 13 (11.9) | 6 (12.2) | 7 (11.7) | 0.93 |
Obesity | 10 (9.2) | 3 (6.1) | 7 (11.7) | 0.51 |
CKD | 14 (12.8) | 8 (16.3) | 6 (10) | 0.33 |
ESRD | 3 (2.8) | 1 (2) | 2 (3.3) | 1.00 |
Cancer | 23 (21.1) | 10 (20.4) | 13 (21.7) | 1.00 |
Cirrhosis | 6 (5.5) | 5 (10.2) | 1 (1.7) | 0.09 |
HIV | 2 (1.8) | 1 (2) | 1 (1.7) | 1.00 |
Social risk factors – n (%) | ||||
Alcohol use | 25 (22.9) | 13 (26.5) | 12 (20) | 0.42 |
Current smoker | 15 (13.8) | 4 (8.2) | 11 (18.3) | 0.17 |
Former smoker | 36 (33) | 21 (42.9) | 15 (25) | 0.05 |
Presenting symptoms- n (%) | ||||
Chest pain | 35 (32.1) | 8 (16.3) | 27 (45) | 0.001 |
SOB | 55 (50.5) | 23 (46.9) | 32 (53.3) | 0.51 |
Shock | 41 (37.6) | 29 (59.2) | 12 (20) | < 0.001 |
Reason for unit admission- n (%) | ||||
Cardiac | 44 (40.3) | 0 (0.0) | 44 (73.3) | < 0.001 |
Respiratory | 14 (12.8) | 9 (18.4) | 5 (8.3) | 0.54 |
Sepsis | 24 (22.0) | 19 (38.8) | 5 (8.3) | < 0.001 |
GI | 11 (10.0) | 9 (18.4) | 2 (3.3) | 0.14 |
Neurological | 7 (6.4) | 6 (12.2) | 1 (1.7) | 0.04 |
Metabolic | 4 (3.7) | 3 (6.1) | 1 (1.7) | 0.32 |
Other | 5 (4.6) | 3 (6.1) | 2 (3.3) | 0.66 |
Table 2 Stress cardiomyopathy diagnosis, complications and outcomes by unit
Overall, n = 109 | MSICU, (n = 49) | CCU, (n = 60) | P value1 | |
Confirmed SC | 62 (56.9) | 12 (24.5) | 50 (83.3) | < 0.0001 |
Clinical SC | 47 (43.1) | 37 (75.5) | 10 (16.7) | |
Hospital day of diagnosis1; median [IQR] | 2 [1-3] | 3 [2-4] | 1 [1-2] | 0.0002 |
Diagnostic Studies – n (%) | ||||
Cardiac catherization | 62 (56.9) | 12 (24.5) | 50 (83.3) | < 0.001 |
Transthoracic echo | 109 (100) | 49 (100) | 60 (100) | |
Lowest ejection fraction – (%); median [IQR] | 35 [28-40] | 30 [30-40] | 35 [30-45] | 0.38 |
TTE anatomical variant- n (%) | ||||
Atypical | 22 (20.2) | 12 (24.5) | 10 (16.7) | 0.31 |
Typical | 87 (79.8) | 37 (75.5) | 50 (83.3) | |
Type of SC- n (%) | < 0.001 | |||
Primary | 43 (39.4) | 0 (0.0) | 43 (71.6) | |
Secondary | 66 (60.5) | 49 (100.0) | 17 (28.3) | |
EKG Findings- n (%) | ||||
Normal EKG | 21 (19.2) | 14 (28.6) | 7 (11.7) | 0.03 |
ST-Segment elevation | 54 (49.5) | 15 (30.6) | 39 (65.0) | < 0.001 |
ST-Segment depression | 4 (3.7) | 2 (4.08) | 2 (3.3) | 1.00 |
T-Wave inversion | 23 (21.1) | 13 (26.5) | 10 (16.7) | 0.24 |
Other | 25 (22.9) | 14 (28.6) | 11 (18.3) | 0.25 |
Complications – n (%) | ||||
ECMO/IABP use | 3 (2.8) | 1 (2.0) | 2 (3.3) | 1.00 |
Inotrope use | 10 (9.2) | 7 (14.3) | 3 (5) | 0.11 |
New arrythmia | 14 (12.8) | 5 (10.2) | 9 (15.0) | 0.57 |
AKI | 37 (33.9) | 21 (42.9) | 16 (26.7) | 0.08 |
RRT | 14 (12.8) | 4 (8.2) | 2 (3.3) | 0.41 |
Acute respiratory failure – n (%) | ||||
Mechanical ventilation | 44 (40.4) | 29 (59.2) | 15 (25.0) | < 0.001 |
NIPPV only | 15 (13.8) | 8 (16.3) | 7 (11.7) | 0.48 |
Shock – n (%) | 41 (37.6) | 29 (59.2) | 12 (20.0) | < 0.001 |
Cardiogenic shock | 14 (12.8) | 5 (10.2) | 9 (15.0) | 0.46 |
Septic shock | 28 (25.7) | 23 (46.9) | 5 (8.3) | < 0.001 |
Other shock | 2 (1.8) | 2 (4.1) | 0 (0.0) | 0.11 |
Follow-up echocardiogram- n (%) | ||||
Repeat echo (% Total) | 69 (63.3) | 30 (61.2) | 39 (65.0) | 0.69 |
Reversibility (% Echo) | 69 (100.0) | 30/30 (100.0) | 39/39 (100.0) | 1.00 |
Clinical SC patients | ||||
Repeat Echo (% Total) | 27/47 (57.4) | 21/47 (44.7) | 6/47 (12.8) | 0.01 |
Reversibility (% Echo) | 27/27 (100.0) | 21/21 (100.0) | 6/6 (100.0) | 1.00 |
Hospital outcomes – n (%) | ||||
In-hospital mortality | 15 (13.8) | 9 (18.4) | 6 (10) | 0.27 |
ICU mortality | 8 (7.3) | 3 (6.1) | 5 (8.3) | 0.73 |
Table 3 Peak laboratory values by unit
MSICU (n = 49) | CCU (n = 60) | P value1 | |
Troponin-T (ng/mL) | 0.42 [0.23-1.2] | 0.87 [0.29-1.54] | 0.11 |
CPK (U/L) | 427 [148.5-1348.5] | 276.5 [161-695] | 0.48 |
Pro-BNP (pg/mL) | 5395 [1458-15000] | 3363.5 [944.5-15369] | 0.72 |
Table 4 Peak laboratory values and outcomes of stress cardiomyopathy by anatomical variant
Typical (n = 87) | Atypical (n = 22) | P value1 | |
Lab findings- median (IQR) | |||
Troponin-T (ng/mL) | 0.65 [0.23–1.57] | 0.58 [0.25-0.94] | 0.61 |
CPK (U/L) | 297.5 [151-919] | 278 [168-631] | 0.94 |
Pro-BNP (pg/mL) | 3722 [874-11932] | 5599 [1608.5-17373.0] | 0.29 |
Hospital complications- n (%) | |||
Inotrope use | 8 (9.2) | 2 (9.1) | 1 |
ECMO/IABP use | 2 (2.3) | 1 (4.5) | 0.5 |
RRT | 3 (3.4) | 3 (13.6) | 0.1 |
Hospital outcomes- n (%) | |||
In-hospital mortality | 12 (13.8) | 3 (13.6) | 1 |
ICU mortality | 7 (8) | 1 (4.5) | 1 |
- Citation: Pancholi P, Emami N, Fazzari MJ, Kapoor S. Stress cardiomyopathy in critical care: A case series of 109 patients. World J Crit Care Med 2022; 11(3): 149-159
- URL: https://www.wjgnet.com/2220-3141/full/v11/i3/149.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v11.i3.149